Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb **Indexed in CAS and CABI, Impact Factor: 8.099**

Post-Vaccination Impact of COVID-19 Vaccines on Human Health: A Comprehensive Assessment of Benefits and Adverse Effects

Dr. Nandlal Kumar Pandit

Ph.D. in Microbiology, RT-PCR LAB Incharge, Sadar Hospital, Banka, Banka District, Bihar, Post as Lab. Teach.

Corresponding Author: nandlalphdjru@gmail.com

Keywords:

COVID-19 Vaccines, Post-Vaccination Impacts, Vaccine Hesitancy, Nanotechnology, Public Health Policy.

ABSTRACT

The post-vaccination era of COVID-19 has generated both remarkable benefits and complex challenges, requiring a comprehensive assessment of its impacts on human health and society. This review synthesizes findings from 2017–2024, covering biomedical, environmental, social, and governance perspectives. Studies confirm that vaccines significantly reduced morbidity and mortality, with mRNA platforms showing the highest efficacy, though waning immunity necessitates booster strategies. Variations in antibody response due to age, BMI, lifestyle, and education emphasize the role of personalized and equitable vaccination approaches. At the same time, environmental concerns such as PPE-derived microplastics and CO_2 emissions highlight the ecological footprint of pandemic responses. Furthermore, sociocultural determinants including mistrust, misinformation, and behavioral psychology shaped vaccine acceptance, underscoring the importance of tailored communication and governance frameworks. Through integrating biomedical innovation, nanotechnology advances, environmental management, and global cooperation, this review offers a multidimensional understanding of post-vaccination outcomes, providing insights for strengthening preparedness against future pandemics.

I. Introduction

The COVID-19 pandemic has reshaped the global health, economic, and social landscape in unprecedented ways. Declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) in January 2020, the pandemic rapidly escalated into one of the most significant public health crises in modern history (Aditama, 2018). By late 2023, more than 771 million confirmed cases and nearly 7 million deaths had been reported worldwide, with more than 13.5 billion vaccine doses administered globally (Zhu, Pang, Liu, & Duan, 2024). Vaccines became the cornerstone of global mitigation strategies, providing protection against severe outcomes while complementing non-pharmaceutical interventions such as masking, quarantine, and social distancing (Iboi, Ngonghala, & Gumel, 2020). However, the post-vaccination period has also been marked by complex outcomes—ranging from remarkable benefits in mortality reduction to concerns over adverse effects, equity, environmental sustainability, and evolving viral variants. This makes a comprehensive assessment of the post-vaccination impacts essential.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

II. Review of Studies on COVID-19 Vaccines, Public Health, and Environmental Impacts

Author(s) & Year	Focus of Study	Key Contributions & Findings	Implications / Relevance
Lupu & Tiganasu (2024)	Relationship between education and COVID-19 vaccination	Found that tertiary education had the strongest influence on vaccine acceptance across 45 LICs, 72 MICs, and 53 HICs. Noted heterogeneity in vaccination rates, with HICs highest.	Education should be integrated into health policies; tailored communication needed for LICs.
Zeng et al. (2024)	Environmental impacts of PPE post-pandemic	PPE components (microplastics, metals, dyes) linked to CO_2 emissions, biodiversity loss, oxidative stress, DNA damage, and human organ/immune disorders. Proposed cradle-to-cradle LCIA framework.	Highlights need for sustainable PPE management to mitigate secondary risks of public health crises.
Zhu, Pang, Liu, & Duan (2024)	Review of COVID-19 vaccines and virus evolution	WHO reported 772M cases, ~7M deaths; vaccine efficacy reduced by mutations. Reviewed vaccine platforms (inactivated, RNA, viral vector, etc.).	Stressed development of broad-spectrum vaccines for long-term pandemic preparedness.
Yadav, Kumar, Mishra, & Saxena (2023)	Global scenario of vaccine development	Reviewed conventional & advanced platforms (RNA, viral vector, VLPs). Noted efficacy variability and local/systemic side effects.	Urged refinement of vaccine technology for higher safety and efficacy.
Visalli et al. (2023)	Personalized vaccinology	Observed that age, BMI, and smoking reduced antibody response, while vitamin D and moderate alcohol intake improved it.	Insights for individualized vaccination strategies.
Prabhakar et al. (2023)	Nanotechnology-driven vaccine innovations	Highlighted >26 nanotech-based vaccines in trials. Applications also included diagnostics, sanitizers, and drug delivery.	Nanotech holds promise for next-gen vaccines and pandemic response tools.
Al-Tohamy et al. (2023)	PPE-derived plastic pollution	Analyzed environmental persistence of face masks. Suggested termite-mediated lignocellulose degradation as a model for plastic breakdown.	Advocated interdisciplinary approaches for eco-friendly PPE disposal.
Zasada et al. (2023)	Global vaccine development pace	Reported 199 vaccines in pre-clinical and 183 in clinical trials by March 2023. First approvals in 2020 marked historic milestone.	Emphasized innovation in vaccine technologies beyond infectious diseases.
Liu & Ye (2022)	Safety & efficacy of vaccine types	Inactivated (60%), adenovirus (65%), mRNA (90%). Booster doses & heterologous strategies found effective.	Supported RNA vaccines' advantages; highlighted waning immunity.
Kałucka et al. (2022)	Vaccination attitudes of healthcare workers in Poland	91.2% vaccinated; doctors & students higher uptake. Main motivator: protecting family health. Concerns: side effects & trial speed.	Insights for HCW-targeted campaigns; type of vaccine influences side effects.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)
Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

Bagdatli & Ipek (2022)	Transport behavior post-pandemic	University students in Istanbul shifted from public/shared transport to cars & micro-mobility.	Policy insights for future urban transit planning.
Dada et al. (2022)	Vaccine hesitancy in Black communities	Barriers: mistrust, misinformation, poor access. Recommended community-based trusted messengers & culturally competent strategies.	Guidance for equity-driven vaccination interventions.
Shahid et al. (2021)	HCWs' vaccine acceptance & side effects	88% vaccinated, 38% mild side effects (myalgia, fever, headache). Most safe with no severe reactions.	Supported safety of vaccines, need for large cohort long-term monitoring.
Acedhars Unilag & Akindele et al. (2020)	Phytomedicines in COVID-19 treatment	Suggested African herbal remedies as potential treatments, highlighting cytokine suppression & viral inhibition.	Advocated integration of traditional medicine into modern frameworks.
Jamshaid et al. (2020)	Global review of treatments & vaccines	Reviewed convalescent plasma, symptomatic therapies, and early vaccine trials.	Stressed diversity of interventions; limited universal efficacy.
Iboi, Ngonghala, & Gumel (2020)	Mathematical modeling of imperfect vaccines	Found 82% vaccination needed for herd immunity at 80% efficacy. With masks, threshold lowered significantly.	Demonstrated synergy between vaccination and non-pharma interventions.
Ranjith (2019)	Public awareness in India	Surveyed 861 respondents; found knowledge gaps, misinformation, inconsistent perceptions.	Showed need for targeted awareness campaigns.
Aditama (2018)	Transition from pandemic to long-term COVID management	WHO declared end of PHEIC in May 2023. Reported 771M cases, 7M deaths, 13.5B vaccine doses.	Called for long-term preparedness for future outbreaks.
Clay (2017)	Behavioral immune system & vaccine attitudes	Higher contamination disgust linked to vaccine hesitancy.	Showed psychological roots of vaccine resistance.
Jahan (2017)	COVID-19 & global security	Framed pandemic as a global security issue requiring multilateral cooperation.	Expanded concept of security to include pandemics and human health.

III. Introduction Post-Vaccination Era of COVID-19

The post-vaccination era of COVID-19 has been characterized by both triumphs and challenges. As summarized by Yadav et al. (2023) and Zasada et al. (2023), vaccines remain the most effective biomedical tool for mitigating the impact of the pandemic, yet they exist within complex socio-political and ecological systems. While studies such as those by Lupu and Tiganasu (2024) and Dada et al. (2022) highlight sociocultural determinants of uptake, others like Visalli et al. (2023) and Liu and Ye (2022) stress biological and immunological variability. The integration of advanced technologies (Prabhakar et al., 2023), environmental considerations (Zeng et al., 2024), and global governance perspectives (Jahan, 2017; Aditama, 2018) further underscores the multidimensional nature of vaccination's impact

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

on human health. This paper aims to build upon these diverse insights, offering a comprehensive assessment of both benefits and adverse effects of COVID-19 vaccines in the post-vaccination era. Through synthesizing biomedical, environmental, and governance perspectives, the study seeks to contribute to future vaccine policy and global pandemic preparedness.

3.1 Global Vaccine Development and Deployment

The speed of vaccine development during COVID-19 was unprecedented in the history of infectious disease control. Within a year of the outbreak, multiple vaccines were granted emergency use authorizations. Zasada et al. (2023) highlighted that by March 2023, nearly 200 vaccines were in pre-clinical stages and over 180 in clinical trials, representing a wide array of platforms such as mRNA, DNA, inactivated, viral vectors, and protein subunits. For the first time in history, novel technologies such as mRNA vaccines were widely deployed at a global scale, setting new benchmarks for innovation in vaccinology. Similarly, Yadav, Kumar, Mishra, and Saxena (2023) noted that platforms such as virus-like particles (VLPs), subunit vaccines, DNA/RNA-based vaccines, and viral vector vaccines were simultaneously in development and deployment, highlighting the breadth of technological responses to the crisis. The scientific community's emphasis was not limited to immediate solutions but also toward future preparedness. Zhu et al. (2024) stressed the challenge of developing broad-spectrum vaccines that could withstand viral mutations, while Prabhakar et al. (2023) discussed how nanotechnology-enhanced vaccines including mRNA, DNA, inactivated, and spike protein-based represented promising innovations with potential for improved delivery, immunogenicity, and stability. These advances underscored the centrality of vaccination in transitioning from emergency crisis management to long-term pandemic preparedness.

3.2 Determinants of Vaccine Uptake and Acceptance

Although vaccines were rapidly developed, equitable acceptance and uptake posed significant challenges. Vaccine hesitancy rooted in social, cultural, and psychological dimensions proved a barrier in many settings. Lupu and Tiganasu (2024) found that educational attainment was a powerful determinant of vaccine acceptance across 170 countries, with tertiary education exerting the strongest positive influence. Their study emphasized the heterogeneity between low-income, middle-income, and high-income countries, urging tailored communication strategies to engage vulnerable groups. Complementing this, Dada et al. (2022) reviewed vaccine hesitancy in Black communities, identifying mistrust, misinformation, and systemic barriers as major factors limiting uptake. They stressed the importance of trusted messengers and culturally competent interventions, particularly in settings with historical injustices.

The behavioral immune system also contributed to vaccine skepticism. Clay (2017) demonstrated that individuals with higher contamination-related disgust sensitivity were more likely to exhibit negative vaccine attitudes. This evolutionary psychological factor underlined why intuitive, emotional reactions often outweighed rational scientific messaging in shaping vaccine hesitancy. Within healthcare systems, uptake varied as well. Kałucka, Kusideł, Głowacka, Oczoś, and Grzegorczyk-Karolak (2022) found that

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

Polish healthcare workers showed a vaccination rate of over 90%, driven by motivations such as personal and family health protection, but tempered by concerns over side effects and trial speed. Shahid, Ghayyur, Majeed, Nisar, and Chaudary (2021) similarly reported that in Pakistan, 88% of healthcare personnel had been vaccinated, though hesitancy remained, with side effects and exposure risks being central issues. Together, these findings highlight how acceptance was shaped not only by education and information but also by professional exposure, cultural background, and psychological predispositions.

3.3 Immunological Responses and Personalized Factors

Post-vaccination immune responses have been far from uniform, reflecting individual biological and lifestyle differences. Visalli et al. (2023) demonstrated that older age, higher body mass index (BMI), and smoking history were negatively associated with antibody production, while moderate alcohol intake and higher vitamin D levels were positively correlated. Their findings offered an important step toward personalized vaccinology, suggesting that vaccine schedules and dosages may eventually need tailoring based on individual health characteristics.

Similarly, Liu and Ye (2022) synthesized clinical and real-world data showing that mRNA vaccines produced the highest efficacy (~90%) compared to adenovirus-vectored (~65%) and inactivated (~60%) vaccines. However, they also noted that antibody levels declined over time, necessitating booster doses. Heterologous prime-boost regimens, they found, induced stronger humoral and cellular responses than homologous ones. Collectively, these studies underscored that while vaccination has been broadly effective, personalized and adaptive strategies are essential to optimize immune responses across diverse populations.

3.4 Post-Vaccination Benefits

The benefits of COVID-19 vaccination have been well documented in terms of reducing morbidity, mortality, and strain on healthcare systems. Zhu et al. (2024) highlighted WHO data estimating that vaccines contributed substantially to controlling the global death toll. Yadav et al. (2023) stressed that vaccination was indispensable in mitigating the life-threatening effects of SARS-CoV-2, especially in vulnerable populations. Beyond immediate disease prevention, Iboi et al. (2020) mathematically demonstrated how imperfect vaccines, combined with non-pharmaceutical interventions like mask-wearing, could dramatically reduce the herd immunity threshold, thereby accelerating pandemic control. Emerging evidence has also linked vaccination to reduced risk of Long COVID. Though not explicitly highlighted in the included studies, this aligns with findings from broader clinical literature and contributes to the assessment of post-vaccination benefits. Additionally, some studies (e.g., Kałucka et al., 2022; Shahid et al., 2021) noted that the majority of post-vaccination side effects were mild and transient, reaffirming the net positive health impact.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

3.5 Adverse Effects and Safety Concerns

Despite benefits, vaccination has not been without risks. Side effects, though generally minor, raised concerns in public discourse. Kałucka et al. (2022) observed that Polish healthcare workers frequently reported mild to moderate symptoms, influenced by vaccine type and pre-existing conditions. Shahid et al. (2021) similarly noted neurological, gastrointestinal, and dermatological side effects in Pakistani healthcare professionals, though severe adverse events were rare.

Broader reviews also distinguished between platforms. Liu and Ye (2022) concluded that inactivated vaccines tended to cause fewer adverse reactions, while mRNA vaccines, despite higher efficacy, occasionally presented risks of stronger immune responses. These observations are consistent with global pharmacovigilance findings, where rare but notable adverse effects such as myocarditis, thrombosis with thrombocytopenia syndrome, and Guillain–Barré syndrome have been identified with specific platforms.

Interestingly, Prabhakar et al. (2023) argued that nanotechnology might not only improve efficacy but also help reduce adverse effects through more precise vaccine delivery and controlled immune stimulation. Their review presented nanotechnology as a bridge between innovation and safety in vaccine science.

3.6 Environmental and Societal Impacts

Beyond human biology, vaccination campaigns and the pandemic response triggered significant environmental and societal consequences. Zeng et al. (2024) and Al-Tohamy et al. (2023) emphasized the environmental toll of massive PPE production and disposal, particularly face masks, which contributed to microplastic pollution, CO_2 emissions, and ecological toxicity. Their reviews called for life-cycle impact assessments and innovative biodegradation strategies. These findings remind us that vaccine-driven public health responses cannot be divorced from their ecological footprint.

Societal impacts also extended to transportation behaviors. Bagdatli and Ipek (2022) found that post-pandemic university students in Istanbul shifted away from buses and shared transit toward private vehicles and micro-mobility options such as e-scooters. While not directly vaccine-related, such behavioral changes were embedded within the broader adaptation strategies of vaccinated societies transitioning toward “new normal” lifestyles.

3.7 Traditional and Complementary Approaches

Alongside modern biotechnology, traditional remedies were also explored. The Acedhars Unilag COVID-19 Response Team and Akindele et al. (2020) reviewed Africa’s phytomedicinal heritage, suggesting that herbal medicines could complement vaccine-based strategies by targeting viral entry and inflammatory pathways. Although they warned against unregulated use, their study highlighted the potential for integrating indigenous knowledge into modern biomedical approaches, thereby expanding the portfolio of tools available in future pandemics.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

3.8 Policy, Governance, and Security Implications

The global rollout of COVID-19 vaccines was as much a governance challenge as a biomedical achievement. Jahan (2017) framed the pandemic as a turning point for global security, stressing the need for unified international cooperation in managing borderless threats. Vaccine distribution inequities between high-income and low-income countries echoed these concerns, demonstrating the necessity of institutional mechanisms for equitable access. Similarly, Aditama (2018) emphasized the importance of transitioning from emergency response to long-term management, noting WHO's decision in May 2023 to declare COVID-19 no longer a global emergency. The future trajectory of vaccine policy, therefore, lies not only in developing better vaccines but also in strengthening multilateral governance frameworks for equitable, sustainable distribution.

IV. Post-Vaccination Impact of COVID-19 Vaccines

The post-vaccination era of COVID-19 has been marked by both remarkable achievements and persistent challenges. Vaccines quickly emerged as the most effective biomedical tool to combat the pandemic, significantly reducing global mortality, morbidity, and hospitalizations. By late 2023, more than 771 million confirmed cases, nearly 7 million deaths, and over 13.5 billion doses of vaccines administered worldwide highlighted the scale of this public health response. The unprecedented speed of vaccine development particularly the introduction of novel platforms such as mRNA, DNA, and viral vector vaccines set new benchmarks for global scientific innovation. These technologies not only provided immediate protection but also opened pathways for long-term preparedness against evolving pathogens. Despite these achievements, vaccine efficacy has been challenged by emerging SARS-CoV-2 variants, necessitating booster doses and heterologous immunization strategies. Studies revealed that immunological responses to vaccines varied widely across individuals, influenced by biological and lifestyle factors such as age, body mass index, smoking history, vitamin D levels, and moderate alcohol intake. This highlighted the importance of moving toward a more personalized approach to vaccinology in the future. While most side effects remained mild and transient, including fever, fatigue, and headache, rare but serious adverse events such as myocarditis and thrombosis were reported in association with certain vaccine platforms, underlining the need for continuous pharmacovigilance. Equally important were the social and cultural determinants of vaccine uptake. Educational attainment played a decisive role in shaping vaccine acceptance, while mistrust, misinformation, and psychological factors such as contamination disgust contributed to hesitancy in various communities. Health care workers, despite their higher rates of vaccination, also reported hesitations related to concerns about side effects and trial speed. These findings reinforced the need for education-driven campaigns, trusted community messengers, and culturally competent communication strategies to enhance equity in vaccine distribution and acceptance. The pandemic also brought forward environmental and societal consequences. The large-scale production and disposal of personal protective equipment, particularly face masks, resulted in severe ecological concerns such as microplastic pollution, CO_2 emissions, and biodiversity loss. Researchers emphasized the urgency of sustainable waste management and innovative biodegradation strategies to minimize these impacts. At the societal level, post-vaccination societies experienced shifts in daily behaviors, such as transportation preferences, reflecting broader adaptations to new realities.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb Indexed in CAS and CABI, Impact Factor: 8.099

Traditional medicine and complementary approaches also entered the discourse, with African phytomedicines being explored as potential supportive remedies alongside vaccines. While promising, these approaches were cautioned against unregulated use, highlighting the need for careful integration of indigenous knowledge into modern biomedical practices. Finally, the vaccine rollout underscored governance and security dimensions. Unequal distribution between high-income and low-income countries revealed deep global inequities, framing vaccination not only as a public health issue but also as a matter of international security and cooperation. Scholars emphasized the importance of strengthening multilateral frameworks and transitioning from short-term emergency responses to long-term pandemic management.

V. Conclusion

The assessment of post-vaccination impacts demonstrates that COVID-19 vaccines remain central to reducing mortality, preventing severe illness, and ensuring global recovery, yet their influence extends far beyond biomedical outcomes. While efficacy levels and safety profiles have varied across platforms, evidence affirms that adverse effects are typically mild and transient, with rare but significant risks requiring continued pharmacovigilance. Individual and sociocultural differences strongly shape vaccine acceptance, highlighting the need for education-driven campaigns, trusted community-based interventions, and personalized immunization strategies. Advances in nanotechnology present promising avenues for both enhancing efficacy and reducing risks, while environmental concerns surrounding PPE waste demand urgent sustainable management solutions. Beyond biology, the pandemic redefined security, governance, and equity debates, exposing gaps in global distribution and cooperation. As COVID-19 transitions from a global emergency to long-term management, the legacy of vaccination lies in its multidimensional impact biomedical, social, ecological, and geopolitical. Strengthening future pandemic preparedness will require not only improved vaccines but also integrated policies that align science, sustainability, and equity.

References

1. Lupu, D., & Tiganasu, R. (2024). Does education influence COVID-19 vaccination? A global view. *Heliyon*, *10*(3).
2. Zeng, F., Liu, D., Xiao, C., Li, K., Qian, X., He, Y., ... & Wang, M. (2024). Advances and perspectives on the life-cycle impact assessment of personal protective equipment in the post-COVID-19 pandemic. *Journal of Cleaner Production*, *437*, 140783.
3. Zhu, C., Pang, S., Liu, J., & Duan, Q. (2024). Current progress, challenges, and prospects in the development of COVID-19 vaccines. *Drugs*, *84*(4), 403-423.
4. Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023). Tracking the COVID-19 vaccines: The global landscape. *Human vaccines & immunotherapeutics*, *19*(1), 2191577.
5. Visalli, G., Lagana, A., Lo Giudice, D., Calimeri, S., Caccamo, D., Trainito, A., ... & Facciola, A. (2023). Towards a future of personalized vaccinology: study on individual variables influencing the antibody response to the COVID-19 vaccine. *Vaccines*, *11*(2), 217.

Indian Journal of Research in Pharmacy and Biotechnology (IJRPB)
www.ijrpb.com ISSN: 2321-5674 (Print), 2320-3471 (Online)

Cross Ref DOI: https://doi.org/10.31426/ijrpb **Indexed in CAS and CABI, Impact Factor: 8.099**

6. Prabhakar, P. K., Khurana, N., Vyas, M., Sharma, V., Batiha, G. E. S., Kaur, H., ... & Kumar, R. (2023). Aspects of nanotechnology for COVID-19 vaccine development and its delivery applications. *Pharmaceutics*, *15*(2), 451.
7. Al-Tohamy, R., Ali, S. S., Zhang, M., Elsamahy, T., Abdelkarim, E. A., Jiao, H., ... & Sun, J. (2023). Environmental and human health impact of disposable face masks during the COVID-19 pandemic: wood-feeding termites as a model for plastic biodegradation. *Applied biochemistry and biotechnology*, *195*(3), 2093-2113.
8. Zasada, A. A., Darlińska, A., Wiatrzyk, A., Woźnica, K., Formińska, K., Czajka, U., ... & Górska, P. (2023). COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic. *Viruses*, *15*(9), 1786.
9. Liu, Y., & Ye, Q. (2022). Safety and Efficacy of the Common Vaccines against COVID-19. *Vaccines*, *10*(4), 513.
10. Kałucka, S., Kusideł, E., Głowacka, A., Oczoś, P., & Grzegorczyk-Karolak, I. (2022). Pre-vaccination stress, post-vaccination adverse reactions, and attitudes towards vaccination after receiving the COVID-19 vaccine among health care workers. *Vaccines*, *10*(3), 401.
11. Bagdatli, M. E. C., & Ipek, F. (2022). Transport mode preferences of university students in post-COVID-19 pandemic. *Transport policy*, *118*, 20-32.
12. Dada, D., Djiometio, J. N., McFadden, S. M., Demeke, J., Vlahov, D., Wilton, L., ... & Nelson, L. E. (2022). Strategies that promote equity in COVID-19 vaccine uptake for black communities: a review. *Journal of urban health*, *99*(1), 15-27.
13. Shahid, S., Ghayyur, A., Majeed, A., Nisar, S., & Chaudary, M. A. (2021). Post-vaccination (COVID-19) impacts in healthcare personnel. *Pakistan Journal of Pharmaceutical Sciences*, *34*.
14. Acedhars Unilag COVID-19 Response Team, Akindele, A. J., Agunbiade, F. O., Sofidiya, M. O., Awodele, O., Sowemimo, A., ... & Odukoya, O. (2020). COVID-19 pandemic: A case for phytomedicines. *Natural Product Communications*, *15*(8), 1934578X20945086.
15. Jamshaid, H., Zahid, F., Din, I. U., Zeb, A., Choi, H. G., Khan, G. M., & Din, F. U. (2020). Diagnostic and treatment strategies for COVID-19. *AAPS PharmSciTech*, *21*(6), 222.
16. Iboi, E. A., Ngonghala, C. N., & Gumel, A. B. (2020). Will an imperfect vaccine curtail the COVID-19 pandemic in the US?. *Infectious Disease Modelling*, *5*, 510-524.
17. Ranjith, M. (2019). Awareness about Covid-19: A Study on Indian Academicians and Students, Healthcare Review, 1 (1), 24-35. *Research Article Abstract The Coronavirus (COVID-19) outbreak came to light when China informed the World Health Organization (WHO) on December*, *31*.
18. Aditama, T. Y. (2018, December). Public Health Management Challenges During COVID-19. In *International Symposium on Chaos, Complexity and Leadership* (pp. 121-128). Cham: Springer Nature Switzerland.
19. Clay, R. (2017). The behavioral immune system and attitudes about vaccines: Contamination aversion predicts more negative vaccine attitudes. *Social Psychological and Personality Science*, *8*(2), 162-172.
20. Jahan, A. (2017). Global Governance and Security Concerns: A new scenario with respect to India. *JOURNAL OF BUSINESS MANAGEMENT & QUALITY ASSURANCE*, *1*(1), 75-79.